Search articles by title, topic or section.
Khabre desk
Recent reporting, analysis and explainers from the multiple myeloma desk.
health
A medRxiv preprint compared matched blood and bone-marrow cell-free DNA from 74 people with multiple myeloma. Peripheral-blood cfDNA matched or exceeded marrow-plasma cfDNA for several genomic signals, while fragment patterns varied by sample compartment and handling.
health
In a randomized phase 2 trial, teclistamab produced deeper responses and longer progression-free survival than lenalidomide-dexamethasone in people with high-risk smoldering multiple myeloma. The study found high rates of complete response and minimal residual disease negativity after fixed-duration treatment.